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Abstract
Understanding the factors that modulate the evolution of virus populations is essential to
design efficient control strategies. Mathematical models predict that factors affecting viral
within-host evolution may also determine that at the between-host level. Although HIV-1
within-host evolution has been associated with clinical factors used to monitor AIDS pro-
gression, such as patient age, CD4 cells count, viral load, and antiretroviral experience, little
is known about the role of these clinical factors in determining between-host HIV-1 evolu-
tion. Moreover, whether the relative importance of such factors in HIV-1 evolution vary in
adult and children patients, in which the course of infection is different, has seldom been
analysed. To address these questions, HIV-1 subtype B (HIV-1B) pol sequences of 163
infected children and 450 adults of Madrid, Spain, were used to estimate genetic diversity,
rates of synonymous and non-synonymous mutations, selection pressures and frequency
of drug-resistance mutations (DRMs). The role and relative importance of patient age, %
CD4, CD4/mm3, viral load, and antiretroviral experience in HIV-1B evolution was analysed.
In the pediatric HIV-1B population, three clinical factors were primary predictors of virus evo-
lution: Higher HIV-1B genetic diversity was observed with increasing children age, decreas-
ing CD4/mm3 and upon antiretroviral experience. This was mostly due to higher rates of
non-synonymous mutations, which were associated with higher frequency of DRMs. Using
this data, we have also constructed a simple multivariate model explaining between 55%
and 66% of the variance in HIV-1B evolutionary parameters in pediatric populations. On the
other hand, the analysed clinical factors had little effect in adult-infecting HIV-1B evolution.
These findings highlight the different evolutionary dynamics of HIV-1B in children and
adults, and contribute to understand the factors shaping HIV-1B evolution and the appear-
ance of drug-resistance mutation in pediatric patients.
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Introduction
HIV-1 populations are characterized by fast evolutionary rates and ample genetic diversity at
both the within- and the between-host levels, which is primarily due to high virus replication
rate, population size, and to the error-prone nature of its reverse transcriptase [1,2]. This high
multi-level genetic variability has relevant implications for both HIV-1 evolution and AIDS
development, as it is involved in the appearance of mutants that resist antiretroviral therapies
(ART) and affects the rate of disease progression [3–6]. Hence, understanding the factors that
modulate the evolution of HIV-1 populations at both the within- and the between-host levels
may provide fundamental insights for developing more efficient strategies to control virus
infection [reviewed by 4]. Despite the importance of this subject, such factors are still only par-
tially understood.
Mathematical modelling of the determinants of RNA virus evolution, as HIV-1, has pro-
posed that virus within- and between-host evolutionary dynamics are linked [7–9]. According
to these models, factors that reduce within-host virus evolutionary rates, such as faster deple-
tion of susceptible cells, lower age of infection at transmission, lower viral replication rates or
control measures (e.g. vaccination, antiviral drugs), may increase between-host ones [7,8],
therefore affecting virus population genetic diversity. Indeed, this association between within-
and between-host evolution has been shown to explain the evolutionary dynamics of several
host-virus interactions [8, 10–12]. For HIV-1, a number of clinical factors used to monitor dis-
ease progression have shown to determine virus within-host evolution in naïve patients: levels
of CD4 count [13,14], viral load [15,16], virus exposure time [2,17], and age [3]. In treated
patients, antiretroviral therapy (ART) has been also shown to promote HIV-1 adaptive evolu-
tion and fixation of drug resistance mutations (DRMs) during the course of the infection (e.g.
[6,18]). These works have demonstrated that, individually, changes in various clinical factors
are associated with HIV-1 evolution. However, this approach might represent an oversimplifi-
cation, as during the course of an infection, or an epidemic, HIV-1 populations face changes
in viral load, CD4 count, and ART experience that occur simultaneously. Therefore, a more
complete understanding of the role of clinical factors in determining the evolution of HIV-1
populations would require of analyses that explore the relative importance of these clinical fac-
tors, and of their interactive effects. Such analyses are scant and do not generally considered
evolution at the between-host level [3,4,19]. Thus, the role of clinical factors in HIV-1
between-host evolution remains largely unexplored [19].
Most of what is known about the clinical factors that shape HIV-1 evolution derives from
analyses in adult patients. Comparatively little is known about the modulators of virus evolu-
tion in pediatric populations, even though over 3 million children currently live with HIV-1
[20]. HIV-1 genetic diversity in infected children may not necessarily evolve in the same way
as in adults, as the course of virus infection is significantly different in these two groups of
patients [21]. First, most HIV-1 infections in children occur perinatally, a time of relative
immunologic immaturity [22]. Therefore, the immune system would exert a smaller selection
pressure in HIV-1 pediatric than in adult populations, and fewer amino acid changes are
expected to accumulate in children-infecting viral genomes at least in the early stages of infec-
tion [23]. Second, kinetics of viral load are also different: in children [24,25], but not in adults
[16], plasma HIV-1 RNA remains elevated over the first two years of infection, and tends to
decrease afterwards. Third, CD4 cells have been described to die at different rates in children
and in adults [22]. Finally, toxicities, suboptimal therapies and/or lack of adherence result in a
large proportion of HIV-infected children receiving multiple ARTs along their lives. Such low-
efficiency treatments have an effect in the evolution of pediatric virus populations, as they
result in the appearance of higher numbers of DRMs as compared with adults [18,26,27]. All
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these differences suggest that the relative importance of clinical factors in determining HIV-1
within-host evolution may vary between children and adult patients, which may affect virus
between-host evolution. However, few studies have aimed at understanding the clinical deter-
minants of the evolutionary rates and genetic diversity in pediatric HIV-1 populations
[3,17,28]. Moreover, comparisons of the evolutionary dynamics of pediatric and adult HIV-1
populations are largely restricted to analyses in mothers and their children, generally involving
small sample sizes [17,28].
To better understand the determinants of HIV-1 between-host evolution in pediatric popu-
lations, we analysed the role of several clinical factors associated with disease progression—CD4
count (both as % CD4 and as CD4/mm3), viral load, patient age/exposure time, and ART expe-
rience—in the between-host genetic diversity of the HIV-1 subtype B in the pediatric cohort of
Madrid, Spain. The Madrid cohort of HIV-infected children and adolescents (from here on
‘pediatric cohort’) belongs to the Cohort of the Spanish Pediatric HIV Network (CoRISpe) [29].
This well described pediatric cohort has a number of characteristics that made it suitable to
address the objectives of the present work. First, it includes patients with detailed follow up
information of infection [30–32] and ART resistance [33–36]. This means that data on the
above-mentioned clinical parameters, as well as virus sequences of the pol gene and frequency
of drug resistance mutations, are available for a large number of individuals [34–36]. Second,
the pediatric cohort includes patients of all ages, from new-borns to 21 years-old patients, many
of which were infected perinatally [33]. This allowed analysing the effect of exposure time/age
in the genetic diversity of HIV-1B populations. Third, the cohort includes naïve, as well as pre-
treated individuals [32–35], so that the effect of ART experience in HIV-1B genetic diversity
could be analysed. Finally, similarly detailed data on an HIV-infected adult cohort from Madrid
is also available (from here ‘adult cohort’) [37,38], such that comparisons between the evolution
of adult and pediatric HIV-1B populations from the same geographical area could be made.
Using this unique data set, we analysed: i) if adult and pediatric HIV-1B populations differed in
their level of between-host genetic diversity; ii) the relative importance of five clinical factor in
determining the between-host evolution of the pediatric HIV-1B population; iii) how changes
in these clinical factors, individually or in combination, were associated with the between-host
genetic diversity of the pediatric HIV-1B population; and iv) whether changes in between-host
genetic diversity were associated with the frequency of DRMs in the pol gene.
Materials and Methods
Study population
The Madrid cohort of HIV-infected children and adolescents was established in 2003. Since
the beginning of the epidemic in Spain, 534 patients have been registered in the cohort, repre-
senting 51.4% of the infected pediatric population in the country. A total of 163 patients from
this cohort were enrolled in the study, which were selected according to: 1) Availability of pol
sequences collected between 1994 and 2015; 2) children being infected only by HIV-1B, to
avoid bias in the estimation of evolutionary parameters due to heterotachy [39]; and 3) Geo-
graphical origin such that all patients were from Spain. Pediatric patients were infected
through mother-to-child transmission. For comparison purposes, a dataset of previously pub-
lished HIV-1B pol sequences from 450 infected adults from the Madrid cohort was used,
including 60% of the mothers from infected children [37,38]. The study dataset included
sequences derived from both ART-experienced and drug naïve patients. For the patients
enrolled in the study, data on age, CD4 counts (percentage and cells/mm3), viral load (HIV-
1B-RNA copies/ml of plasma, c/ml), and presence of drug resistance mutations at the moment
of HIV-1B sampling for sequence determination were collected (S1 File).
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Sequence data
Partial sequences of the pol gene from pediatric patients are described in [34], and sequences
from adult patients were collected from different sources [33–35]. Sequences encompassed
334 amino acids: the 297 amino acids of the viral protease (PR), and a fragment coding for the
first 37 amino acids of the reverse transcriptase (RT) (1,002 nucleotides, positions 2,255–3,256
of HXB2 subtype B reference strain, GenBank accession number K03455). A full list of Gen-
Bank accession numbers and year of isolation, the corresponding publication, and the relevant
clinical parameters associated with each sequence is available in S1 File. Sequence alignments
were constructed using MUSCLE 3.7 [40] and adjusted manually according to the amino acid
sequences using Se-Al [41].
Genetic diversity and selection pressures
Genetic diversity (d) was estimated as average pairwise nucleotide differences, using the
Tamura-Nei Tamura-Nei, the Kimura 2-parameter and the composite likelihood nucleotide
substitution models as implemented in MEGA 7 [42]. Since all models led to the same conclu-
sions, for simplicity only values obtained using the Tamura-Nei model are presented. Standard
errors (SE) of each measure were calculated using pairwise distances and were based on 1,000
bootstrap replicates for permutation tests. Selection pressures were measured as the ratio
between the mean number of non-synonymous (dN) and synonymous (dS) nucleotide substi-
tutions per site (dN/dS) using the single-likelihood ancestor counting (SLAC), the fixed effect
likelihood (FEL), the random effects likelihood (REL), and the fast unbiased Bayesian approxi-
mation (FUBAR) methods implemented in the HyPhy package [43]. Because the four methods
led to the same conclusions, only the FUBAR results are shown. In all cases, dN/dS estimates
were based on input neighbor-joining trees inferred using the MG94 nucleotide substitution
model. Individual values of dN and dS were also obtained.
Detection of recombination
Recombination breakpoints were detected using four different methods available in the RDP4
package: RDP, GENECONV, Bootscan, and Chimaera, and employing the default parameters
[44]. Only recombination signals detected by all the methods (P<0.05) were considered as
positive. The HIV-1B data sets used in this study did not contain recombinant sequences.
Drug resistance mutations
Drug-resistance mutations among naïve patients were defined according to the mutation list
for Transmitted Drug Resistances (TDR) surveillance as recommended by the WHO [45], and
were mapped using the Calibrated Population Resistance tool [46]. Drug-Resistance Mutations
(DRM) in treated patients were defined by the International AIDS Society-USA list (IAS) [47].
Drug susceptibility was estimated for protease inhibitors (PI), nucleoside and non-nucleoside
reverse transcriptase inhibitors (NRTI and NNRTI, respectively), according to the HIVdb
Interpretation Algorithm version 6.0.11 (Stanford University, Palo Alto, CA, USA) [48].
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Statistical analyses
Differences in genetic diversity, synonymous and non-synonymous diversity and selection pres-
sures were calculated using parametric (General Linear Models, GLM) and non-parametric (Per-
mutation tests) analyses. Since both approaches led to similar conclusions, for simplicity, only
GLM analyses are shown. Variation in the frequency of sites under diversifying/purifying selection
was analysed by Fisher’s exact test, with a Yates correction for small sample size when necessary
[49]. The relative importance of each clinical factor on the pediatric cohort was estimated using a
Principal Component Analysis. Children age (years), ART experience (presence or absence), %
CD4 cells, CD4/mm3, and VL (c/ml) were scaled to zero mean and unit variance, inserted in a
regression matrix and rotated to obtain the principal components (PCs). Significance thresholds
for the load of each ecological factor on a PC were determined using a broken-stick model [50].
Multivariate tests were used to analyse the association between clinical factors and evolu-
tionary parameters of the pediatric HIV-1B population [49]. A set of models that included a
global model containing all clinical factors, and nested models that contained different combi-
nations of the clinical factors was fitted for each evolutionary parameter using GLM (R library:
lm), and linear mixed models (R library: nlme). Since both analyses yielded similar results, for
simplicity only GLM data is presented. We used this approach because it allowed us to make
inferences across a set of causal model structures for each evolutionary parameter [51]. Global
and nested models containing clinical parameters as predictor variables were ranked according
to Akaike’s Information Criteria (AIC) (R library: AICcmodavg), and the model with the low-
est AIC score was selected as the best-ranked model. We calculated AIC Delta (Δi), as the dif-
ference between the AIC of a given model and that of the best-ranked model. Delta quantifies
how strongly models compete (Δi = 0 for best-ranked model; Δi = 1–2 indicates substantial
empirical support; Δi = 4–7 indicates considerable less support; and Δi> 10 indicates no sup-
port [51]). For all evolutionary parameters, at least one model closely competed with the best-
ranked model. Therefore, we also calculated a relative importance index (ωi) for each predictor
using multi-model inference [51], following the expression: ωi = exp(-0.5Δi)/Sexp(-0.5Δi). The
larger the ωi, the greater the likelihood of the model given the data, relatively to the competing
models. The relative importance of the predictor variables included in each model was calcu-
lated by hierarchical partitioning of the correlation coefficient (R library: relaimpo).
Results
Comparison of HIV-1B evolution and relative importance of clinical
factors in pediatric and adult HIV-1B populations
Evolutionary parameters of the HIV-1B populations were estimated based on virus sequences
from 163 pediatric, and the same number of adult, patients. Note that our sequence dataset
included 450 adult patients (Table 1). In order to avoid sample size effects, minimize biases
due to differences in CD4 count, viral load and ART experience; and maximise the ‘clock-like-
ness’ of the data, we created a ‘balanced’ dataset following [52]. Accordingly, we randomly
removed sequences from the adult cohort to have the same number of instances than in the
pediatric cohort, with the same naïve/treated proportion and with similar distribution of
patients across CD4 count (both as CD4/mm3 and % CD4 cells) and viral load categories
(Table 1). This randomization was repeated ten times and HIV-1B evolutionary parameters
were estimated in each ‘balanced’ dataset. Average values of the ten ‘balanced’ datasets did not
significantly differ between them and from the real data (S1 Table), indicating that they are
representative of the HIV-1B population in adult patients. Data presented in the Results sec-
tion correspond to average values for the ten ‘balanced’ datasets.
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HIV-1B genetic diversity was lower in the pediatric than in the adult-infecting virus popula-
tion (d: 0.054±0.002 vs. 0.058±0.002; F = 27.09, P<1x10-5), which was due to a lower synony-
mous diversity (dS: 0.145±0.001 vs. 0.165±0.002; F = 215.40, P<1x10-5) (Table 2). Non-
synonymous diversity was similar in the pediatric and adult virus populations, and always
Table 1. Clinical and epidemiological parameters of the pediatric and adult HIV-infected populations used in this study.
Parameter Children n = 163 Adults n = 450
Naive n = 30 Treated n = 133 Total n = 163 Naive n = 207 Treated n = 243 Total n = 450
Gender [n]
Female 23 69 92 173 50 223
Male 7 64 71 18 19 37
Unknown 0 0 0 16 174 190
Route of transmission [n]
Vertical 30 133 163 0 0 0
IDU 0 0 0 44 24 68
Sexual (MSM+Htsex) 0 0 0 122 24 146
Others 0 0 0 38 194 232
Unknown 0 0 0 3 1 4
CD4+ T cell counts [%]
<25% 10 46 56 77 24 101
26–50% 10 64 74 105 153 258
>50% 1 1 2 0 9 9
Unknown 9 22 31 25 57 82
CD4+ T cell counts [Cells/mm3]
<350 4 13 17 69 42 89
350–500 4 11 15 46 31 77
500–1000 7 51 59 47 88 157
1000–1500 2 15 17 11 10 21
>1500 4 14 18 9 15 24
Unknown 9 29 38 25 57 82
Viral load [HIV-1 RNA-copies/ml]
<50 3 11 14 0 0 0
50–500 3 13 16 2 1 3
500–1,000 3 5 8 7 1 8
1,000–10,000 3 33 36 32 11 43
10,000–100,000 6 33 39 94 152 246
>100,000 11 19 30 47 21 68
Unknown 1 19 20 25 57 82
DRM prevalencea [n]
At least one DRM M 7 106 113 21 104 125
To PIsb 1 49 50 5 38 43
To NRTIs 4 92 96 14 92 106
To NNRTIs 5 63 68 8 66 74
None 22 27 49 186 139 325
IDU: injectable drug users; MSM: men who have sex with men; Htsex: heterosexual; DRM: drug resistance mutations; PI: protease inhibitors; NRTI:
nucleoside reverse transcriptase inhibitors; NNRTI: non-nucleoside reverse transcriptase inhibitors.
a DRM prevalence was determined following the WHO TRM list for ‘naïve’ patients [40], and the IAS–USA 2014 list for ‘treated’ patients [41].
b Includes only major drug-resistance mutations at the viral protease.
doi:10.1371/journal.pone.0167383.t001
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smaller than synonymous diversity (dN: 0.031±0.004 vs. 0.030±0.002; F = 1.56, P = 0.834). Con-
sequently, the two virus populations were under purifying selection, this being weaker in the
pediatric than in the adult HIV-1B population (dN/dS: 0.212±0.009 vs. 0.180±0.002; F = 922.34,
P<1x10-5) (Table 2). Accordingly, the majority of the amino acid sites were under purifying
selection in both virus populations (Fig 1), but this proportion was higher in the adult than in
the pediatric populations (242/334 vs. 175/334; χ2 = 28.65, P<1x10-5). The pediatric and adult
HIV-1B populations had the same proportion of sites under diversifying selection (16/334).
The lower number of sites under purifying selection in the pediatric virus population was
accompanied by a higher frequency of sequences harbouring at least one DRM, as compared
with the adult virus population (113/163 vs. 44/163; χ2 = 58.5, P<1x10-5). When only site
known to be associated with drug resistance were considered, sites under purifying selection
were more abundant in the adult- than in the pediatric-infecting virus population (32/47 vs.
20/47; χ2 = 6.20, P = 0.013). The proportion of drug-resistance sites under diversifying selec-
tion did not vary between pediatric and adult HIV-1B populations (3/47 vs. 2/47; χ2 = 0.05,
P = 0.823) (Fig 1). Hence, HIV-1B evolution differs in pediatric and adult patients.
The pediatric and adult cohorts differed in average CD4/mm3 and viral load, but not in %
CD4 (Table 2). Thus, we further analysed whether the relative importance of CD4 cells count
(both %CD4 and CD4/mm3), VL (c/ml), children age, and of ART experience, also differed in
the pediatric and adult cohorts of patients by including these variables in a Principal Compo-
nent Analysis (PCA) (Table 3). In the pediatric cohort, such PCA yielded three main Principal
Components (PCs) that collectively explained 84% of the total variance. Children age was
highly associated with PC1, ART experience with PC2 and CD4/mm3 with PC3 (Squared
loadings 91.2%). In the adult cohort, PCs 1, 2 and 3 were associated with ART experience,
VL and % CD4, respectively, age being associated with the less important PC (Table 3). Thus,
the relative importance of the five clinical parameters analysed also differed between the pedi-
atric and the adult cohorts.
Given that the HIV-1B between-host evolution and the relative importance of the analysed
clinical factors differed in pediatric and adult cohorts, we studied how these clinical factors
affected the between-host evolution of the pediatric HIV-1B population, and we used the
adult-infecting virus population for comparison purposes.
Table 2. Evolutionary parameters of the pediatric and adult HIV-1B populations based on a fragment of the pol gene (1,002 nt).
Parameters Pediatric (age 0–21) Adult (age >21)
Naïve Treated Total Naïve Treated Total
Evolutionary
d 0.047±0.002 0.061±0.002 0.054±0.002 § 0.059±0.001 0.056±0.001 0.058±0.002 *
dN 0.023±0.000 0.039±0.000 0.031±0.004 § 0.028±0.000 0.031±0.000 0.030±0.002
dS 0.143±0.002 0.147±0.000 0.145±0.001 0.178±0.003 0.152±0.002 0.165±0.002 §*
dN/dS 0.163±0.003 0.262±0.001 0.212±0.009 § 0.158±0.002 0.203±0.002 0.180±0.002 §*
Clinical
% CD4 23.82±3.02 28.40±1.03 27.67±0.99 25.38±02.02 34.17±18.24 29.74±6.31
CD4/mm3 1224.33±280.17 980.05±85.65 1,010.84±82.62 501.41±20.20 529.64±205.56 515.42±45.79 *
VL (c/ml) 588,773.27±219,049.43 98,397.45±29,810.18 177,722.95±45,527.78 § 87,847.41±7,816.82 67,548.55±9,404.65 77,776.66±
7,782.99 *
§ indicates significant differences between naïve and treated individuals within either pediatric or adult HIV-1B populations.
* indicates significant differences between pediatric and adult populations for total values.
doi:10.1371/journal.pone.0167383.t002
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Relative contribution of clinical factors to the between-host evolution of
pediatric HIV-1B populations
We explored the relative contribution of five clinical factors to the evolution of the pediatric
HIV-1B population. To do so, we estimated d, dN, dS and dN/dS for each sequence in the pedi-
atric HIV-1B population by averaging values of each evolutionary parameter derived from
pairwise comparisons with the rest of the sequences in the data set. For each evolutionary
Table 3. Principal component analysis of five clinical factors from 163 pediatric and adult HIV-1B infected patients of the Madrid cohort.
Pediatric (age 0–21) Adult (age >21)
Principal Component 1 2 3 4 5 Principal Component 1 2 3 4 5
Percent association component-variable
Age 91.2 1.9 0.3 0.1 7.5 ART experience 95.8 0.1 0.0 4.0 0.1
ART experience 0.0 93.7 2.3 3.9 0.1 VL 0.1 95.6 1.2 2.9 0.2
CD4/mm3 1.0 2.2 94.7 2.0 0.1 % CD4 0.0 1.2 96.4 2.4 0.0
VL 0.3 5.4 2.7 84.6 7.0 CD4/mm3 5.2 3.7 3.1 87.9 0.1
% CD4 11.6 0.1 0.2 8.4 79.7 Age 0.2 5.2 6.5 3.1 85.0
Expected values under broken-stick model 20.8 20.3 20.2 19.8 18.9 20.3 21.2 21.4 20.0 17.1
Total variance explained by the component 40.7 30.0 13.6 10.5 5.2 44.8 25.4 18.8 5.9 5.1
doi:10.1371/journal.pone.0167383.t003
Fig 1. Selection pressures in amino acid residues of the pol protein. Number of amino acid residues (aa) of the
protease (PR) and the retrotranscriptase (RT) proteins under purifying and diversifying selection, and under neutral
evolution, in pediatric (A) and adult (B) HIV-1B populations. Data are presented either considering all sites or only
those associated with drug resistance. Amino acid residues associated to antiretroviral resistance were chosen
according to IAS-USA 2014 [47].
doi:10.1371/journal.pone.0167383.g001
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parameter we fit a global model containing all the clinical factors, and a set of nested models
containing all possible combinations of the clinical factors, and we calculated the AIC for each
model. The model with the lowest AIC (best-ranked model) was considered as the best in pre-
dicting values of each evolutionary parameter (Table 4). The best-ranked model for d, dN and
dN/dS in the HIV-1B pediatric population included the clinical factors children age and ART
experience, which explained more than half of the variation in these evolutionary parameters
(R2>0.55). The models including CD4/mm3 and children age, ART experience and CD4/
mm3, or combining CD4/mm3, ART experience and children age closely competed with the
best-ranked model (Δi<4; R2>0.47). However, ωi for these models was two- to three-fold
smaller than for the best-ranked model (Table 4), indicating that the best-ranked model was
significantly better than models with Δi<4. The rest of the models poorly predicted d, dN and
dN/dS (Δi> 4; R2<0.30). Ambiguous results were obtained for dS, as up to ten models closely
Table 4. Model selection analyses for genetic diversity (d), rate of synonymous (dS) and non-synonymous substitutions, and selection pressures
(dN/dS). Model structures included children age (Age), ART experience (ART), CD4 count (both as % CD4 and as CD4/mm3), and viral load (VL). Best-ranked
models are bolded and have the lowest AIC value.
Model structure1 R2 logLik AIC2 Δi3 ωi4
d
ART (61%) + Age (39%) 0.55 315.05 -620.90 0 0.335
ART (80%)+ CD4/mm3(20%) 0.55 315.05 -618.11 2.79 0.083
ART (55%) + Age (35%) + CD4/mm3 (10%) 0.55 315.05 -618.10 2.80 0.054
Age (71%) + CD4/mm3(29%) 0.47 312.62 -617.23 3.67 0.054
dN
ART (61%) + Age (39%) 0.66 337.21 -664.91 0 0.364
ART (61%)+ CD4/mm3(39%) 0.61 337.40 -662.79 2.12 0.126
ART (54%) + Age (32%) + CD4/mm3 (14%) 0.61 337.40 -662.78 2.13 0.125
Age (58%) + CD4/mm3(42%) 0.57 335.58 -661.16 3.75 0.056
dS
VL (100%) 0.37 242.07 -476.94 0 0.195
CD4/mm3(100%) 0.29 241.46 -474.93 2.01 0.071
VL (75%) + %CD4 (25%) 0.38 242.28 -474.55 2.39 0.059
Age (100%) 0.25 241.26 -474.53 2.41 0.058
VL (92%) + ART (8%) 0.38 242.26 -474.52 2.42 0.058
VL (89%) + Age (11%) 0.37 242.09 -474.17 2.77 0.049
VL (99%) + CD4/mm3 (1%) 0.37 242.07 -474.15 2.79 0.048
ART (100%) 0.10 241.05 -474.09 2.85 0.047
%CD4 (100%) 0.07 241.04 -474.08 2.86 0.047
Age (64%) + %CD4 (36%) 0.34 241.77 -473.54 3.40 0.036
CD4/mm3 (80%) + %CD4 (20%) 0.33 241.74 -473.48 3.46 0.035
dN/dS
ART (73%) + Age (27%) 0.57 48.38 -86.96 0 0.274
ART (63%)+ CD4/mm3(37%) 0.57 48.51 -85.03 1.93 0.104
ART (56%) + Age (31%) + CD4/mm3 (14%) 0.57 48.49 -84.98 1.98 0.102
Age (58%) + CD4/mm3(42%) 0.54 47.12 -84.24 2.73 0.070
ART (51%) + Age (31%) + CD4/mm3(12%) + VL (6%) 0.58 48.91 -83.82 3.14 0.057
1 Identity of clinical factors and their corresponding relative importance in each predictive model of each HIV-1B evolutionary parameter.
2AIC, Akaike’s Information Criterion.
3 Where i = the model in question and 0 = best-ranked model.
4 AIC model weight; the larger theω, the greater the likelihood of the model given the data, relatively to the competing models [51].
doi:10.1371/journal.pone.0167383.t004
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competed with the best-ranked model, and none of them explained more than 37% of the vari-
ance in dS (Table 4). Thus, children age, ART experience and CD4/mm3, which explained the
majority of the variance in the HIV-1B-infected pediatric cohort of patients, were also the best
predictors of virus evolution. We therefore analysed in more detail the effect of these three
clinical factors in the evolution of the pediatric HIV-1B population.
Association of children age with the evolution of the pediatric HIV-1B
population
To analyse the effect of children age in the between-host evolution of HIV-1B, we divided the
pediatric cohort into four age categories following the CDC recommendations, so that our
results could be clinically meaningful [53]: 0–2 years old, 2–8 years old, 8–13 years old and 13–
21 years old, with between 30 and 50 sequences each. We also included the adult cohort as an
additional age category (Fig 2). To control for sample size effects we created ten balanced data-
sets with 30 (smallest sample size across children age categories) randomly-sampled HIV-1B
sequences from the adult-infecting 163-sequence datasets, and evolutionary parameters in
these balanced datasets did not significantly differ from those in the real data (S2 Table). Thus,
we kept the 163-sequence datasets for consistency with our previous analyses.
HIV-1B population genetic diversity increased with children age (from 0.049±0.004 to
0.064±0.003; F = 166.97, P<1x10-5) (Fig 2A). Interestingly, this increase in HIV-1B genetic
diversity with children age was primarily due to an increase in the rate of non-synonymous
substitutions (dN: from 0.026±0.002 to 0.042±0.001; F = 311.22, P<1x10-5) (Fig 2B), whereas
the rate of synonymous substitutions remained similar across age categories (dS: 0.147±0.001
to 0.148±0.001; F = 0.52, P = 0.471) (Fig 2C). Consequently, purifying selection was weaker at
increasing children age (dN/dS: from 0.178±0.001 to 0.283±0.003; F = 269.77, P<1x10-5) (Fig
2D), although the frequency of sites under purifying and diversifying selection did not change
across age categories (67/334 to 79/334 and 7/334 to 11/334, respectively; χ2<1.01, P>0.798).
In the adult virus population, d and dN were smaller than in children over 2 years old (Fig 2A
and 2B), and dS was higher than in every children age category (Fig 2C). Thus, purifying selec-
tion in the adult HIV-1B population was stronger than in every children age category (Fig 2D).
To analyse whether the changes in the rate of non-synonymous substitutions across chil-
dren age categories were associated with HIV-1B drug resistance, we determined the number
of virus sequences harbouring DRMs across children age categories (Fig 2E). Such frequency
was higher at increasing children age (from 23% to 69%; χ2 = 6.84, P<0.009), and always
higher than in the adult HIV-1B population (10%) (Fig 2E). The proportion of pediatric HIV-
1B sequences harbouring mutations conferring resistance to nucleoside reverse transcriptase
and protease inhibitors (NRTI and PI, respectively) significantly increased across age catego-
ries (χ2>4.49, P<0.034): from 13% and 20% in 0–2 years old patients, to 67% and 38% in 13–
21 years old patients, respectively. The proportions of HIV-1B sequences harbouring muta-
tions conferring resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI) also
increased across age categories (from 23% to 48%), but this increase was not significant (χ2 =
1.63, P = 0.202) (S3 Table). The frequency of drug resistance-associated sites under purifying
and diversifying selection did not change across age categories (7/47 to 10/47 and 0/47 to 3/47,
respectively; χ2<4.77, P>0.261).
Association of ART experience with the evolution of the pediatric HIV-1B
population
We compared d, dN, dS and dN/dS in virus populations infecting naïve (n = 30) and treated
children (n = 133), including in the analyses the corresponding adult-infecting HIV-1B
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population (Table 2). Again, we controlled for sample size effects by creating ten balanced
datasets with 30 (number of naïve HIV-1B pediatric sequences in our dataset) randomly sam-
pled HIV-1B sequences from treated pediatric patients. Evolutionary parameters in these bal-
anced datasets did not significantly differ from those in the real data (S4 Table), such that we
kept data from the 133-treated sequences dataset.
In pediatric patients, HIV-1B genetic diversity was higher in treated than in naïve pediatric
patients (0.061±0.002 vs. 0.047±0.002; F = 268.34, P<1x10-5). This was due to a nearly 2-fold
Fig 2. Association between HIV-1B evolution and children age. HIV-1B genetic diversity (A), rate of non-
synonymous (B) and synonymous (C) substitutions, selection pressures (D), and frequency of sequences with DRMs
(E) in the pediatric HIV-1B population across children age categories. Data of the corresponding adult-infecting HIV-1B
populations is also presented. Values in naïve patients (red squares), treated patients (green triangles), and grouping
both classes of patients (blue circles) are shown. Values indicate mean±standard error. Note the different scale in each
panel.
doi:10.1371/journal.pone.0167383.g002
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difference in the rate of non-synonymous substitutions (dN: 0.039±0.000 vs. 0.023±0.000;
F = 513.69, P<1x10-5), whereas no significant differences in the rate of synonymous substitu-
tions were observed (dS: 0.143±0.002 vs. 0.147±0.000; F = 1.98, P = 0.260). Accordingly, purify-
ing selection was weaker in the treated than in the naïve HIV-1B pediatric population (dN/dS:
0.262±0.001 vs. 0.163±0.003; F = 429.02, P<1x10-5) (Table 2). The frequency of sites under
purifying selection was lower in naïve than in treated virus populations (26/334 vs. 137/334;
χ2 = 105.81, P<1x10-5), with no changes in the frequency of positively selected sites (7/334 vs.
11/334; χ2 = 0.91, P = 0.339). In adult patients, HIV-1B genetic diversity and the rate of non-
synonymous substitutions did not differ between naïve and treated virus populations (d: 0.059
±0.003 vs. 0.056±0.003, dN: 0.028±0.002 vs. 0.031±0.003; F<1.03, P>0.126). However, the rate
of synonymous substitutions was higher in the HIV-1B naïve population (dS: 0.178±0.003 vs.
0.152±0.002; F = 735.72, P<1x10-5), due to stronger purifying selection (dN/dS: 0.158±0.002 vs.
0.203±0.002; F = 947.16, P<1x10-5) (Table 2). The frequency of sites under purifying and
under diversifying selection did not vary between naïve and treated virus populations (227/334
vs. 216/334 and 16/334 vs. 18/334, respectively; χ2<0.17, P>0.680). Interestingly, although d,
dN and dS were higher in naïve adult than in naïve pediatric HIV-1B populations, the opposite
trend was observed in treated patients (Table 2).
In pediatric patients, the proportion of sequences harbouring at least one DRM was signifi-
cantly higher in the treated than in the naïve virus population (106/133 vs. 7/30, χ2 = 35.36,
P<1x10-4). The same trend was observed when the frequency of PI, NRTI and NNRTI muta-
tions was analysed separately (S3 Table). In the naïve HIV-1B pediatric population, only 17%
of the sites associated with drug resistance were under purifying selection; while in the treated
population 43% of the sites were under purifying selection (8/47 vs. 20/47; χ2 = 7.32, P = 7x10-3)
(Fig 3). Only one site was found to be under diversifying selection in HIV-1B populations of
treated patients and none in virus populations of naïve pediatric patients (Fig 3). In HIV-1B
infected adults, the proportion of sequences harbouring at least one DRM was again higher in
treated than in naïve virus populations (56/133 vs. 3/30, χ2 = 10.93, P = 1x10-3), with the same
trends for PI, NRTI and NNRTI mutations (S3 Table). In naïve adult patients, 80% of the sites
associated with drug resistance were under purifying selection; while in the treated population
around 60% of the sites were under purifying selection (38/47 vs. 28/47; χ2 = 5.09, P = 0.024)
(Fig 3). No differences in the frequency of sites under diversifying selection among HIV-1B
populations in adults were observed (1/47 vs. 3/47; χ2>0.11, P<0.617). When pediatric and
adult HIV-1B populations were compared, the proportion of sequences harbouring DRMs
was higher in the pediatric than in the adult virus population for both treated and naïve
patients (χ2>2.29, P<0.049). The number of drug resistance-associated sites under purifying
selection was higher in adult than in pediatric virus populations both in naïve and in treated
patients (χ2>5.19, P<0.019), this difference being much larger in naïve patients (Fig 3).
Association of children CD4 count with the evolution of the pediatric HIV-
1B population
To analyse the role of the concentration of CD4 cells (CD4/mm3) in HIV-1B evolution, we
divided both the pediatric and adult cohorts into five categories as defined by the CDC classifi-
cation [53]:>1500 CD4/mm3, 1500–1000 CD4/mm3, 1000–500 CD4/mm3, 500–350 CD4/
mm3 and <350 CD4/mm3, with between 12 and 57 sequences each, and we estimated the
same evolutionary parameters as above (Fig 4 and S1 Fig). In the pediatric HIV-1B population,
genetic diversity decreased with increased CD4/mm3 (d: from 0.071±0.004 to 0.056±0.002;
F = 62.52, P<1x10-5) (Fig 4A). This decrease of HIV-1B genetic diversity was due to a reduc-
tion of dN (dN: from 0.048±0.001 to 0.031±0.000; F = 102.60, P<1x10-5) (Fig 4B), while dS
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remained constant across CD4/mm3 categories (dS: from 0.159±0.001 to 0.150±0.001; F = 1.56,
P = 0.213) (Fig 4C). Accordingly, purifying selection was weaker at lower CD4 count (dN/dS:
from 0.317±0.003 to 0.215±0.002; F = 65.91, P<1x10-5) (Fig 4D). The frequency of sites under
purifying and diversifying selection did not vary across CD4/mm3 categories (8/334 to 20/334
and 1/334 to 6/334, respectively; χ2<0.49, P>0.493). In the adult HIV-1B population, HIB-1B
genetic diversity (d: 0.052±0.002–0.065±0.006; F<1.53, P>0.217) did not significantly change
with increasing CD4/mm3 (S1 Fig). Similarly, both dN and dS did not vary at increasing CD4/
mm3 (dN: 0.024±0.001–0.032±0.000; dS: 0.155±0.005–0.195±0.010; F<2.58, P>0.108). Finally,
Fig 3. Selection pressures and prevalence of mutations in amino acid residues associated with
antiretroviral drug resistance. Selection pressures in amino acid residues associated with drug resistance
in pediatric and adult HIV-infected patients according to their ART experience. Sites under diversifying
selection are in green; sites under purifying selection are in red. Sites under neutral evolution are in blue. DRM
prevalence was determined following the WHO TRM list for ‘naïve’ patients [45], and the IAS–USA 2014 list
for ‘treated’ patients [47]. PI: protease inhibitors; NRTI: nucleoside reverse transcriptase inhibitors; NNRT:
non-NRTI; TDR: transmitted drug resistance; DRM: drug resistance mutations. Dashes: not a major mutation
in treated patients.
doi:10.1371/journal.pone.0167383.g003
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neither selection pressures (dN/dS: 0.147±0.012–0.174±0.002; F = 3.38, P = 0.423), nor the fre-
quency of sites under purifying and diversifying selection (84/334 to 95/334 and 1/334 to 4/
334, respectively; χ2<0.53, P>0.527) did vary across CD4/mm3 categories.
Interactive effects of clinical factors in the evolution of the pediatric HIV-
1B population
Because the best-ranked models explaining HIV-1B evolution in pediatric populations were
those including ART+Age and ART+CD4/mm3 (Table 4), we focused in these two interac-
tions. We used the HIV-1B sequence datasets from naïve and treated patients, and in each of
them we explored how d, dN, dS and dN/dS varied both across age and across CD4 count cate-
gories (Figs 2 and 4).
HIV-1B genetic diversity in naïve pediatric patients remained constant across age categories
(d: 0.047±0.004–0.049 ±0.003; F = 0.30, P = 0.824). Similar results were obtained when dN
(0.023±0.001–0.028±0.002; F = 1.05, P = 0.373) and dS (0.125±0.016–0.150±0.004; F = 0.95,
P = 0.417) were analysed separately. Accordingly, selection pressures did not vary with chil-
dren age (dN/dS: from 0.151±0.006 to 0.223±0.046; F = 2.01, P = 0.115) (Fig 2). In addition, the
proportion of virus sequences harbouring NRTI and NNRTI mutations increased from 13% to
33%, and the proportion of sequences with PI mutations from 0% to 33%. However, these
increases were not significant (χ2<0.74, P>0.390) (S3 Table). On the other hand, in treated
Fig 4. Association between HIV-1B evolution and CD4 cells count. HIV-1B genetic diversity (A), rate of non-
synonymous (B) and synonymous (C) substitutions, and selection pressures (D) in the pediatric HIV-1B population
across CD4/mm3 categories. Values in naïve patients (red squares), treated patients (green triangles), and grouping
both classes of patients (blue circles) are shown. Values indicate mean±standard error. Note the different scale in each
panel.
doi:10.1371/journal.pone.0167383.g004
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patients virus d increased with age (d: from 0.053±0.004 to 0.065±0.003; F = 81.71, P<1x10-5),
which was due to a smaller increase in dS (dS: 0.141±0.001–0.156±0.002; F = 63.14, P<1x10-5),
and to a larger increase in dN (dN: 0.030±0.001–0.043±0.001; F = 86.92, P<1x10-5). Conse-
quently, purifying selection was weaker with increasing children age (dN/dS: from 0.213±0.010
to 0.289±0.003; F = 25.92, P<1x10-5) (Fig 2). The proportion of HIV-1B sequences harbouring
NRTI mutations significantly increased across age categories, from 31% in 0–2 years old
patients to 71% in 13–21 years old patients (χ2 = 5.26, P>0.022). The proportions of HIV-1B
sequences harbouring NNRTI and PI mutations also increased across age categories (from
39% to 55% for NNRTI mutations, and from 31% to 41% for PI mutations), but this increase
was not significant (χ2<0.74, P>0.390) (S3 Table). Values of all the analysed evolutionary
parameters were generally higher in the HIV-1B population of treated than of naïve children
(Fig 2).
Analyses in HIV-1B naïve pediatric populations across CD4/mm3 categories indicated that
genetic diversity (d: 0.059±0.005–0.051±0.005), the rate of synonymous (dS: 0.138±0.007–
0.172±0.020) and non-synonymous (dN: 0.020±0.002–0.026±0.002) substitutions, and selec-
tion pressures (dN/dS: 0.129±0.015–0.175±0.021) did not depend on CD4/mm3 values
(F<0.93, P>0.460) (Fig 4). In treated children, HIV-1B genetic diversity decreased at larger
CD4/mm3 values (d: 0.072±0.004 to 0.057±0.002; F = 18.30, P<1x10-5). This was due to a
decrease of dN (dN: 0.052±0.002 to 0.032±0.001; F = 18.30, P<1x10-5), whereas dS did not vary
across CD4/mm3 categories (dS: 0.149±0.005–0.153±0.005; F = 2.03, P = 0.088). Hence, purify-
ing selection in the HIV-1B population was stronger with increasing CD4/mm3 (dN/dS: from
0.346±0.013 to 0.208±0.008; F = 20.25, P<1x10-5). Values of all the analysed evolutionary
parameters were higher in the HIV-1B population of treated than of naïve children, with the
exception of dS (Fig 4).
Thus, the observed greater HIV-1B genetic diversity with increased children age and
reduced CD4 count can be mainly attributed to virus evolution in treated pediatric patients,
and specifically to an increase in the rate of non-synonymous substitutions. Moreover, such
increase is accompanied by a higher frequency of drug resistance mutations.
Discussion
It is currently well-know that the course of HIV infection and the virus epidemiological
dynamics differ in pediatric and adult patients [4,22,24,25,28]. Given such differences, it might
seem obvious that virus evolution would be different in children and adults. However, to date
there is little experimental evidence of such differences. We performed a detailed analysis of
HIV-1B evolution in comparable adult and pediatric cohorts that differ in clinical and epide-
miological traits. Indeed, patients of our study adult cohort had on average lower concentra-
tion of susceptible cells and reduced levels of HIV-1 replication as compared with those of the
pediatric cohort. Moreover, both cohorts also differed in relevant traits for virus epidemiology:
Transmission rates were higher in the adult cohort than in the pediatric cohort of Madrid
[35,37]; and the primary mode of HIV-1B transmission was also different, as the pediatric
cohort only contained patients infected by mother-to-child transmission. Such variation in
clinical and epidemiological factors was accompanied by differences in HIV-1B evolution in
children and adults: Genetic diversity was higher in adult- that in children-infecting HIV-1B
populations, due to a higher rate of synonymous substitutions in the adult HIV-1B population.
Accordingly, purifying selection was weaker in viruses infecting pediatric patients than in
adults. Mathematical models on the evolution of RNA viruses (like HIV-1) predict that, in
populations with different epidemiological dynamics, factors affecting within-host virus evolu-
tion such as decrease of susceptible cells and lower viral replication rates, would accelerate
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between-host virus evolution [7,8]. This would explain the higher genetic diversity in adult-
infecting HIV-1B populations. Two conditions need to be met to establish this link between
within- and between-host evolution: First, host age of infection (i.e. exposure time to the virus
sensu [54]) upon transmission must be different in the two host populations. In our study,
there is a marked difference in the age of infection as all patients from the pediatric cohort
were perinatally infected, whereas this was not so in the adult cohort. Second, within-host evo-
lutionary rates must change over the course of infection. Here, we have not measured within-
host evolutionary rates, as we did not count with sequential samples of the same patient. How-
ever, indicatives of lower within-host virus evolutionary rates, such as depletion of target CD4
cells as well as changes in viral load during the course of the HIV-1B infection [8], have been
reported for both the adult and the pediatric cohorts of Madrid [37,38]. Thus, the analysed
populations meet the conditions to establish an association between within- and between-host
evolution. Indeed, our results would be also in agreement with experimental analyses in other
RNA viruses that explained changes in evolutionary rates across virus populations as a func-
tion of contact rates, replication rates, speed of depletion of susceptible individuals and/or the
mode of transmission [8,10–12].
The observed differences in HIV-1B evolution between children and adults suggested that
the relative importance of the factors driving virus evolution might differ in these two virus
populations. However, experimental analyses of the clinical factors driving HIV-1 evolution
are largely restricted to adult patients. Thus, we focused in the pediatric HIV-1B population.
The factors detected by our PCA analyses as defining traits of the pediatric cohort (ART expe-
rience, children age and CD4/mm3, which together explained 85% of the total variance in the
pediatric cohort) had the greatest impact on the variance in HIV-1B d, dN, and dN/dS. The
CD4/mm3 had the lesser impact in these evolutionary parameters, this factor being included
only in some of the best-raked models and having lower relative importance. In contrast, viral
load and percentage of CD4 cells did not appear to contribute meaningfully to HIV-1B evolu-
tion in children. Importantly, the best-ranked models explained 55–66% of the variance in the
HIV-1B evolutionary parameters (except for dS). Such values are evidence that the combined
effect of the clinical factors considered in these models significantly determine between-host
HIV-1B evolution, and with different relative importance. Accordingly, previous works attrib-
uted a role to ART experience, children age and CD4 count as determinants of within-host
HIV-1 evolution of adult and children cohorts when considered individually [3,17,18,55,56].
Still, in our models part of the variance in HIV-1B between-host evolutionary parameters
remained unexplained, which indicate that clinical factors other than those considered here
have an effect in the evolution of pediatric HIV-1B populations. For instance, due to lack of
information in the analysed cohort we have not considered the type/number of ARTs under-
gone by each patient, or adherence to treatment, which have been proposed to partially deter-
mine HIV-1B evolution [21,25,36]. The lack of such information would potentially blur our
model selection analysis if only certain drug combinations would affect virus evolution, which
would therefore yielded a poor predictive power of ART experience in HIV-1B evolution in
our analyses. However, our approach was robust enough to detect ART experience as a major
factor in virus evolution. In any case, future work that will add these factors as predictors
would contribute to a finer mapping of HIV-1B evolution determinants.
We further explored how the most relevant clinical factors for HIV-1B evolution modulated
virus between-host evolution in pediatric patients. Our results indicate that HIV-1B genetic
diversity increases with children age. It is important to note that the pediatric patients included
in our analyses were perinatally infected, so that in our study population children age and age
of infection are largely equivalent. However, both have been shown to similarly affect HIV-1B
evolution [3,17]. In perinatally infected children, lower HIV-1 genetic diversity at younger age
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(or early stages of infection) has been associated with genetic drift [57] due to severe bottle-
necks during mother-to-child transmission (e.g. [58,59]), but also with selection of HIV-1 vari-
ants adapted to vertical transmission (reviewed by [60]). Our results provide some insights on
which of these two phenomena may determine the genetic diversity of the analysed HIV-1B
population in younger children. If genetic drift were the major driver, we would expect that
the HIV-1B population in children under 2 year-old were a random representation of that in
the equivalent adult population, and therefore with similar genetic diversity [61]. However,
genetic diversity in children from 0 to 2 year-old was significantly lower than in adults, which
suggests that certain selection is acting on the virus variants that are vertically transmitted.
After perinatal transmission, very high rates of HIV-1 replication have been detected in youn-
ger infected children that can persist for long periods of time, especially in untreated patients
[25,62]. High rates of virus replication increase HIV-1B population sizes and, due to the error-
prone nature of the HIV-1B polymerase, may result in random accumulation of mutations in
the virus population. Such accumulation would increase the genetic diversity of the virus pop-
ulation with children age/age of infection, which would explain our results. However, two of
our observations argue against this possibility. First, viral load was a poor predictor of virus
genetic diversity; hence within-host population size is not a factor in determining between-
host evolution of HIV-1B in pediatric patients of the Madrid cohort. Second, larger virus pop-
ulation sizes are often associated with increasing rates of synonymous mutations [2,9], but we
observed that higher HIV-1B genetic diversity was rather accompanied by higher rates of non-
synonymous mutations. Therefore, the observed changes in virus genetic diversity across age
categories are likely the consequence of adaptive changes, rather than of neutral evolution.
The most obvious forces shaping HIV-1B adaptive evolution may be host- and/or environ-
mental-related selection pressures; i.e., the strength of the host immune system and/or antivi-
ral drugs, respectively. These two types of selection pressures are linked to two of the clinical
factors detected as predictors of HIV-1B evolution: CD4 count and ART experience. At early
stages of infection, the children immune system is still immature, exerting a smaller selection
pressure on the virus population [22,23]. With increasing children age, the virus is subjected to
stronger selection pressures to overcome the immune system [3,63]. If this were the major
mechanism shaping the evolution of the pediatric HIV-1B populations from Madrid, the anal-
ysis of virus evolutionary parameters in the entire virus pediatric population would mimic the
observations in naïve children. However, analyses of changes in evolutionary parameters of
pediatric virus populations across both age and CD4 count categories indicated that such
changes were associated with HIV-1B evolution in ART experienced, but not in naïve, chil-
dren. Moreover, the interaction between children age and ART experience, and of CD4 count
and ART experience, were the best predictors of virus population d, dN, and dN/dS, ART expe-
rience having always the highest relative importance. These results indicate that the roles of
children age/age of infection and of CD4 count in the pediatric HIV-1B evolution are likely
linked to the effects of ART, and highlight the importance of considering the combined effect
of different clinical factors to better understand HIV-1 evolution. Our findings are at odds
with previous analyses that failed in finding a significant interaction between children age/age
of infection and ART experience in determining the genetic diversity of pediatric HIV-1B pop-
ulations [3]. However, such work considered children between 0 and 4 year-old, which might
not be enough time span to detect the ART x Age interaction. Indeed, some of the trends
observed in our study population would disappear if we would restrict our analyses to the
youngest age categories (Fig 2).
Altogether, our results strongly suggest that ART experience is a major determinant of
pediatric HIV-1B genetic diversity. Hence, we would expect that virus evolution would favour
the fixation of mutations conferring ART resistance. In our study population, the frequency of
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DRMs in the HIV-1B pediatric population increased with children age, in parallel with
changes in the virus genetic diversity and the rate of non-synonymous substitutions, in partic-
ular in ART experience children. This is compatible with the central role of ART experience in
pediatric HIV-1B evolution, and suggests that the same factors affecting HIV-1B evolution
influence the fixation of DRMs. Thus, the genetic diversity of pediatric HIV-1B populations
could be a good predictor of the virus ability to generate DRMs, and our results may also serve
as scaffolding for building mathematical models aiming at predicting the conditions that
favour the appearance of DRMs in children.
Supporting Information
S1 Fig. Association between HIV-1B evolution and CD4/mm3 in adult patients. HIV-1B
genetic diversity (A), rate of non-synonymous (B) and of synonymous (C) mutations, and
selection pressures (D) in the adult-infecting HIV-1B population across CD4/mm3 categories.
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